HHS & Healthcare Contracts Intelligence — March 13, 2026

$185M obligated (options to $907M), 47% outlayed by 2026 on 8+ year contract targets high-threat viruses.

Two full/open awards to nonprofit and small business underscore sustained biodefense priority despite early outlay divergence (2% vs 47%).

Early-stage low outlays (2% on $795M) risk delays/cost overruns under firm-fixed-price structure.

Long horizons (to 2032) expose to HHS budget shifts or threat priority changes.

$722M untapped options + extensions could 5x MAPP's current obligation.

BARDA's OTA/competitive awards favor repeat biotech R&D players with $795M precedent.

$980M obligations in NAICS 541714 reflect priority on long-duration biotech for health security threats like viruses.

{"entity"=>"MAPP Biopharmaceutical", "reason"=>"47% outlay + $722M options signal near-term scaling in viral countermeasures.", "trigger"=>"Option exercises >$100M or 2030 extension"}

{"entity"=>"Advanced Technology International", "reason"=>"2% outlay on $795M tests execution on largest award; OTA repeat potential.", "trigger"=>"Outlays exceed $50M/quarter or new BARDA task orders"}

{"entity"=>"BARDA Biotech Pipeline", "reason"=>"Divergent outlay paces highlight funding concentration risk/opportunity.", "trigger"=>"FY2027 budget increase >10% for NAICS 541714"}